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Coffee consumption is a model for addictive behavior. We performed a meta-analysis of
genome-wide association studies (GWASs) on coffee intake from 8 Caucasian cohorts
(N=18 176) and sought replication of our top findings in a further 7929 individuals. We also
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performed a gene expression analysis treating different cell lines with caffeine. Genome-wide
significant association was observed for two single-nucleotide polymorphisms (SNPs) in the
15q24 region. The two SNPs rs2470893 and rs2472297 (P-values= 1.6 1011 and 2.7 1011),
which were also in strong linkage disequilibrium (r2 = 0.7) with each other, lie in the 23-kb long
commonly shared 50 flanking region between CYP1A1 and CYP1A2 genes. CYP1A1 was found
to be downregulated in lymphoblastoid cell lines treated with caffeine. CYP1A1 is known to
metabolize polycyclic aromatic hydrocarbons, which are important constituents of coffee,
whereas CYP1A2 is involved in the primary metabolism of caffeine. Significant evidence
of association was also detected at rs382140 (P-value = 3.9 1009) near NRCAM—a
gene implicated in vulnerability to addiction, and at another independent hit rs6495122
(P-value =7.1 1009)—an SNP associated with blood pressure—in the 15q24 region near
the gene ULK3, in the meta-analysis of discovery and replication cohorts. Our results from
GWASs and expression analysis also strongly implicate CAB39L in coffee drinking. Pathway
analysis of differentially expressed genes revealed significantly enriched ubiquitin protea-
some (P-value = 2.2 1005) and Parkinson’s disease pathways (P-value =3.6 1005).
Molecular Psychiatry advance online publication, 30 August 2011; doi:10.1038/mp.2011.101
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Introduction
Coffee is the most widely used beverage worldwide
with known health benefits.1–3 Coffee drinking has
been associated with a decreased risk of dementia and
Alzheimer’s disease (AD), Parkinson’s disease4 and
type II diabetes.5 However, coffee intake has also been
associated with increased risk of some cancers,6–8
blood pressure9–10 and myocardial infarction.11 The
contradictory epidemiological findings on coffee
intake and its effects on various diseases may be
attributed to the different contents of coffee. Apart
from caffeine, its most well-known constituent that
stimulates the central nervous system, coffee is a
source of complex organic compounds with beneficial
anti-oxidant and endocrine properties.12,13 However,
roasting of coffee beans is known to produce
polycyclic aromatic hydrocarbons,14 which are a class
of carcinogenic chemicals that are formed by incom-
plete combustion of organic matter. At unusually high
doses, coffee is known to have potentiating effects on
mutagenesis,13 including cytotoxicity of X-rays, ultra-
violet light and chemotherapeutic agents.13 Most of
these mutagenic effects are known to be independent
of caffeine15 and have been attributed to aliphatic
dicarbonyls15–17 and hydrogen peroxide.16
The P450 system in the liver has a key role in coffee
metabolism. The cytochrome P4501A1 encoded by
the gene CYP1A1 is known to metabolize polycyclic
aromatic hydrocarbons such as benzo(a)pyrene. The
caffeine content (B100mg per cup of coffee) is
primarily metabolized in the liver by the cytochrome
P450 CYP1A2, and is further broken down by
the enzymes CYP2A6 and NAT2.18–21 Most of the
biological effects of caffeine including those on the
brain and the central nervous system are mediated
through antagonism of the adenosine receptors,
specifically the A1 and A2A receptors.22 Accumulat-
ing evidence from a number of sources points to
the A2A receptor as the main target for caffeine.23
Under normal conditions, adenosine is hypothesized
to activate the adenosine receptors, leading to
subsequent activation of adenylyl cyclase and Ca2þ
channels.22 Adenosine acts to inhibit the release of
neurotransmitters. Antagonism of the adenosine path-
way leads to many downstream changes including
changes in the dopaminergic system that result in
decreased affinity of dopamine for the dopamine
receptors24 and changes in gene expression. It is
through these mechanisms that caffeine mediates its
effects on the brain and behavior.22 These changes in
gene expression are not well understood, but the use
of microarrays may give insights into the molecular
changes brought about by caffeine.25
Ordinary caffeine use has generally not been
considered to be a case of drug abuse, and is indeed
not so classified in DSM-IV (Diagnostic and Statistical
Manual of Mental Disorder), but caffeine may be a
model drug for studies of abuse,26 and withdrawal
effects when coffee consumption is stopped have
been discussed. Many users experience withdrawal
symptoms, which include headache, decreased alert-
ness and concentration, as well as depressed mood
and irritability.27,28 Beneficial effects from caffeine
include improved psychomotor speed,29 mood30 and
alertness.31 Several studies have shown that subjects
reported higher levels of alertness and concentration
along with increased appetite for work.22,30 Some have
postulated that the positive effects can be explained
by a reversal of the withdrawal symptoms in habitual
users,32,33 but this has been refuted by studies of
caffeine intake in non-habitual users.34,35 It is also
clear that some users experience negative effects such
as insomnia, anxiety and dysphoria.36,37 Caffeine
consumption is also known to have a role in suicide.38
Genetic studies in twins suggest that the heritability
estimates of coffee consumption range from 0.39 to
0.56.30,39,40 Most genetic studies have focused on
caffeine and have restricted the gene search primarily
to polymorphisms in the CYP1A2 and ADORA2A
genes. Metabolism of caffeine by the CYP1A2 enzyme
shows substantial variation between people,41,42
because of both genetic and environmental factors.43
There is some evidence, although not genome-wide
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significant, that polymorphisms in the gene are
known to moderate the association between coffee
consumption and hypertension44 and myocardial
infarction,11 as well as the risk of breast cancer in
BRCA1 carriers.45 No association has been found
between variants in CYP1A2 and caffeine consump-
tion,23 but an single-nucleotide polymorphism (SNP)
in this gene (rs762551) has been shown to be associ-
ated with high inducibility of the CYP1A2 enzyme in
smokers.46 A candidate gene study associated a
polymorphism in the ADORA2A gene (rs5751876)
with caffeine consumption23 in a Costa Rican sample.
This SNP has also been implicated in increasing
risk to panic disorder in two separate studies in
Caucasian populations,47,48 but none of the findings
on ADORA2A reached genome-wide significance nor
were they replicated. Among environmental factors,
age and sex are known to affect coffee consumption.28
Coffee consumption patterns may also differ from
country to country based on its geographical location,
religious preferences, availability of coffee and its
cost; however, large differences remain between
individuals within populations, presumably reflect-
ing coffee preference, which is also known to be
influenced by genetic variation.28
We conducted a meta-analysis of genome-wide
association studies (GWASs) including >18 000
individuals to identify common genetic variants that
influence coffee consumption. We tested for associa-
tion with >2.6 million polymorphisms that tag the
vast majority of common human genetic variation. We
combined the GWAS results with gene expression
data from cells differentially treated with caffeine to
identify genes the pattern of expression of which is
changed after caffeine treatment and which harbor
polymorphisms that show evidence of association.
Materials and methods
Study populations
This study included participants from eight cohorts
including the following:
Erasmus Rucphen Family. The ERF (Erasmus
Rucphen Family) study is a family-based study that
includes > 3000 participants descending from 22
couples living in the Rucphen region in the
nineteenth century. All living descendants of these
couples and their spouses were invited to participate
in the study. The frequency of coffee consumption
was assessed with a questionnaire. A total of 1814
participants who had both phenotype and genome-
wide genotype data (54% women)49 were available for
the analysis.
Cooperative health research in the Augsburg region
(KORA). The KORA F4 study is a follow-up study to
the KORA-Survey 2000 (S4, October 1999 to July
2001). It was conducted between October 2006 and
May 2008. From the KORA F4 survey (full cohort
n=3080), 1814 individuals aged between 32 and 81
years were selected for genotyping on the Affymetrix
1000K50 chip (Affymetrix, Santa Clara, CA, USA).
Coffee consumption was assessed with a questionnaire
asking the number of cups of coffee consumed per day.
Rotterdam Study (RS-I and RS-II). The Rotterdam
Study-I (RS-I) is a prospective population-based
cohort study of 7983 residents aged X55 years
living in Ommoord, a suburb of Rotterdam (The
Netherlands). Coffee consumption was assessed
with a food frequency questionnaire. In total, 4139
individuals who had both phenotype and genotype
data were used in the analysis.51 The RS-II is a
prospective population-based cohort study of 3011
residents aged X55 years , and coffee consumption
was assessed in the same manner.
Netherlands Twin Register. A sample of (mostly)
adult twins was obtained from the NTR
(Netherlands Twin Register), which was established
in 1987 and contains information about Dutch
twins and their families voluntarily participating
in research.52 Since 1991, every 2–3 years, a
questionnaire is mailed to adult twins and their
family members registered with the NTR. These
questionnaires contain items about health, lifestyle
and personality. In 2000, the fifth NTR survey was
sent out,53 and contained the question, ‘On average,
how many cups of caffeinated coffee do you drink in
one day?’ This survey was completed by 6782
subjects; data on coffee consumption were available
for 6673 subjects. The mean age of the respondents
was 30.0 years (s.d. 10.9). Genome-wide genotyping
was available for 1087 subjects with coffee data.
The Study of Health in Pomerania. The SHIP (Study
of Health in Pomerania) is a longitudinal population-
based cohort study in West Pomerania. The baseline
sample SHIP-0 comprised 4308 subjects.54,55 Coffee
consumption was assessed with the question, ‘How
many cups of caffeinated coffee do you drink per
day?’ In total, 2125 individuals (77.4% women) with
both phenotype and genome-wide genotype data were
available for the analysis.
TwinsUK. The TwinsUK cohort consisted of a
group of twins ascertained to study the heritabi-
lity and genetics of age-related diseases (http://
www.twinsUK.ac.uk). These unselected twins were
recruited from the general population through
national media campaigns in the United Kingdom
and were shown to be comparable to age-matched
population singletons in terms of disease-related and
lifestyle characteristics.56,57 The TwinsUK I and
II cohorts consist of twins from the adult twin
British registry, also shown to be representative of
singleton populations and UK population.56 Coffee
consumption was assessed by questionnaire, and
genome-wide genotype and imputed data were
available for 1092 (TwinsUKI) and 1919 (TwinsUKII)
samples. Ethics approval was obtained from the Guy’s
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and St Thomas’ Hospital Ethics Committee. Written
informed consent was obtained from every parti-
cipant in the study.
Queensland Institute of Medical Research (QIMR). Twins
recruited from the Australian Twin Registry were mailed
to a Health and Lifestyle Questionnaire between 1980
and 1982. Twins were recruited through national
media campaigns. As part of the questionnaire, parti-
cipants were asked ‘How many cups of coffee would
you drink on average per day?’28 The age range of respon-
dents was 17–88 years with a mean age of 31 years.
Both phenotype and genotype information were avail-
able for 1988 unrelated individuals. Detailed descriptions
of phenotyping, genotyping, imputation and quality
control (QC) protocol are given elsewhere.28,58
Genotyping and imputation
The participating cohorts were genotyped on commer-
cially available platforms including Affymetrix, Illu-
mina (San Diego, CA, USA) and Perlegen (Mountain
View, CA, USA) (Supplementary Table 1). Quality
control was performed in each group separately. The
overall criteria were to exclude individuals with
low call rate, excess heterozygosity and gender
mismatch. On the basis of sample size and study-
specific characteristics, different criteria were used
(Supplementary Table 1). Imputations of non-geno-
typed SNPs in the HapMap CEU v22 were carried out
within each study using MACH59,60 or IMPUTE.61,62
Genome-wide association and meta analysis
We conducted a meta-analysis of 10 GWASs from
8 cohorts, consisting of > 18 000 individuals and
B2.6. million imputed and genotyped SNPs. For
each GWAS, the association analysis was performed
using linear regression analysis by regressing coffee
categories63 on age, sex and SNP allele dosage in
ProbABEL64 (GenABEL.org, Novosibirsk, Russia),
SNPTEST65 (Jonathan Marchini, Oxford, UK) or
QUICKTEST (Toby Johnson, Lausanne, Switzerland)
(http://toby.freeshell.org/software/quicktest.shtml)
(Supplementary Table 1). The coffee categories were
defined as (1) 0–2 cups per day, (2) 3–4 cups per day,
(3) 5–6 cups per day, (4) 7–9 cups per day and (5)X10
cups per day.63 For ERF, which is a family-based
cohort, the analysis was performed using a mixed
model66,67 incorporating a relationship matrix esti-
mated from the genotyped data.68 A fixed-effects
meta-analysis was conducted in METAL using the
inverse variance-weighted method. All SNPs that had
a low minor allele frequency ( < 0.01) and low imputa-
tion quality (Rsq/proper_info < 0.3) were dropped
from the meta-analysis. Genomic control correction
was also applied to all cohorts before meta-analysis.
Heterogeneity between studies was assessed with
Cochran’s Q-test in METAL.
Replication analysis
We sought in silico replication of the SNPs that showed
a P-value <1 1006 (Table 1) in an independent Ta
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Dutch cohort (LifeLines, N=7929, % of women=57).
The LifeLines Cohort Study was a multi-disciplinary
prospective population-based cohort study examining
in a unique three-generation design the health and
health-related behaviors of 165 000 individuals living
in the North East region of The Netherlands. All survey
participants were between 18 and 90 years of age
at the time of enrollment. Recruitment had been
going on since the end of 2006, and until January
2011, >40000 participants were included. Genotyping
for LifeLines was performed on Illumina CytoSNP12
v2. Genetic imputations were performed in BEAGLE
(Brian L. Browning, Seattle, WA, USA) v3.1.0 using
build 36 HapMap CEU v22 as the reference popula-
tion. Statistical analysis was performed in PLINK
using the same analysis model as in the discovery
phase. Random-effects meta-analysis was performed
for the top hits in the ‘rmeta’ library of the R package.
Gene expression analysis
We used public gene expression databases for
lymphocytes and the brain to examine the expression
of genes implicated by the GWAS69–71 (http://eqtl.
uchicago.edu/cgi-bin/gbrowse/eqtl/). In addition, we
performed caffeine treatment on three different cell
types as part of a project to find inherited protein-
truncating mutations by Gene Inhibition of Nonsense
Mediated Decay:72 (1) lymphoblastoid cell lines
(LCLs) established from the blood of 24 females from
hereditary non-BRCA1/2 breast cancer families
recruited into the Kathleen Cuningham Foundation
for Research into Breast Cancer (kConFab), (2) a cell
line newly established from a breast-to-bone metas-
tasis and (3) the colon cancer cell line, HT29.
Experiments were performed in triplicate for each
sample. Optimization experiments determined cell
number and caffeine concentration for each cell type.
For LCLs, 3.5 106 cells were plated in 10ml of tissue
culture medium (RPMI-1640 supplemented with 10%
fetal calf serum) containing 7.5mM caffeine (Sigma,
St Louis, MO, USA). For both the HT29 and the bone
metastasis cell line, 1 106 cells were plated in 10ml
of tissue culture medium (RPMI-1640 supplemented
with 10% fetal calf serum) 24 hours before treating
cells with media containing 10mM caffeine (Sigma).
All cell lines were incubated with caffeine for a total
of 8 h at 37 1C in a humidified atmosphere containing
5% carbon dioxide. Matching untreated cells were
used as controls.
Total RNAwas extracted from both caffeine-treated
and untreated control cells using the RNeasy RNA
extraction kit (Qiagen, Hilden, Germany) as per
the manufacturer’s instructions. Biotinylated cRNA
was prepared from 450ng total RNA using the
Illumina TotalPrep RNA amplification kit (Ambion,
Foster City, CA, USA). After quantification using a
ND-1000 spectrophotometer (Nanodrop Technologies,
Wilmington, Delaware, USA), a total of 156 samples
(750ng cRNA per sample) were hybridized to Human
HT-12 Expression BeadChips (Illumina) using all
manufacturer’s reagents for washing, detecting and
scanning as per the whole-genome gene expression
direct hybridization assay protocol (Illumina).
The HumanHT-12 Expression BeadChips (Illumina)
contains 48803 probes that cover >25000 annotated
genes. Expression data were collated and quality
checked in the Illumina BeadStudio and then imported
into GeneSpring V10.0 (Agilent Technologies, Santa
Clara, CA, USA). Data were quantile normalized to the
baseline of the median of all samples and then filtered
using an Illumina detection score of >0.95 in at least
one sample. To identify differentially expressed genes
between each caffeine-treated sample to its own
untreated control, a linear model was implemented
using R and the LIMMA (Smyth, 2004)73 package.
Data were adjusted for multiple testing with a false
discovery rate of 5%. Two criteria were used to select
the set of relevant genes. First, a set of genes with a
log odds>0 (B-statistic) was selected, followed by a
hierarchical search of genes based on log-fold changes.
Gene lists were then imported into GeneSpring V10.0
(Agilent Technologies) for data visualization and to
determine overlapping genes between different cell
types. To see which biological pathways are signi-
ficantly enriched, a pathway analysis was performed
using PANTHER74 of all genes that showed signi-
ficant differential expression after correction for multi-
ple testing (P-value<Bonferroni’s threshold=0.05/
48803=1 1006) in at least one cell type. An addi-
tional test was performed to test for enrichment of
specific biological pathways or canonical functions in
the Ingenuity Pathway Analysis program (Ingenuity
Systems, Inc., Redwood City, CA, USA).
Results
Genome-wide association analysis
The descriptive statistics of each cohort are provided
in Supplementary Table 2. Genome-wide association
results are provided in Supplementary Figure 1, and
the quantile–quantile plot is provided in the Supple-
mentary Figure 2. In the classical GWAS, two SNPs
rs2470893 and rs2472297 exceeded the genome-wide
significance threshold of 5 1008, with the best hit
rs2470893 (P=2.3 1008) (Table 1). The two SNPs
are in strong linkage disequilibrium (LD) (r2 = 0.70)
and are located at 15q24, between the genes CYP1A1
and CYP1A2 (Figure 1). Significant heterogeneity
between studies was detected at both loci
(rs2470893, PHET = 0.01 and rs2472297, PHET = 0.0008)
(Supplementary Table 3), although the direction
of the effect for the top hit was consistent across
all populations (Figure 2). Neither of the SNPs are
in strong LD with rs762551, the SNP previously
identified as increasing CYP1A2 activity in caffeine-
administered smokers (r2 = 0.12 and r2 = 0.06,
respectively), and rs762551 showed only nominal
significance in the analysis (P=0.003). The minor ‘T’
allele of the most significant SNP rs2470893 was
consistently positively associated with coffee con-
sumption across all the cohorts with effect estimates
ranging from 0.013 to 0.169 (Figure 2). rs2470893 was
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genotyped in four cohorts, and in these, the minor
allele frequency ranged from 0.26 to 0.35. Imputation
quality was high in the other cohorts ranging from
0.79 to 1. The association signals at the CYP1A1/
CYP1A2 locus remain unchanged when a separate
analysis adjusted for smoking status was performed in
the two cohorts: ERF (rs2470893, P-value = 8.51004
and rs2472297, P-value = 8.81004) and RS-II
(rs2470893, P-value = 5.3 1007 and rs2472297,
P-value= 6.3 1008), which were the primary cohorts
driving the association signal at 15q24.
Figure 1 shows that there are a number of signals
in other genes in the chromosome 15 region. A
strong association was observed for rs6495122
(P=8.22 1008) (Table 1). This SNP is located at
chromosome 15q24 in the intergenic region between
the genes ULK3 and CPLX3 and does not appear
to be in strong LD with the two best hits in
this region (rs2470893, r2 = 0.175 and rs2472297,
r2 = 0.086) (Figure 1). A secondary conditional asso-
ciation analysis of the 15q24 region in RS-II (which
was the largest contributor to the association signal
at 15q24, P-value = 8.4 1006) adjusting for the
most significant finding (rs2470893) revealed nom-
inal association of rs2472297 (P-value = 4.41002)
and moderate association of rs6495122 (P-value =
1.1 1003) and rs12487 (P-value= 7.7 1004) with
coffee drinking (Supplementary Figure 3).
Other SNPs on different chromosomes that showed
strong evidence of association (P-values below 1006)
are listed in Table 1. These include rs16868941, which
is an intronic SNP in the NCALD gene (P-value=
1.5 1007; Supplementary Figure 4); rs382140,
an intergenic SNP between the genes LAMB4
and NRCAM (P-value=3.3 1007; Supplementary
Figure 5) and rs9526558, an intronic variant
within CAB39L (P-value=6.79 1007; Supplemen-
tary Figure 6). No heterogeneity was detected at any
of these loci (Table 2).
Replication analysis
Table 2 provides results from replication analysis and
the meta-analysis of discovery and replication
cohorts. Replication was sought for six SNPs pre-
sented in Table 1, which necessitated a Bonferroni-
corrected significance threshold of 8.31003. Owing
to bad imputation quality in the replication cohort,
no replication was performed for rs9526558. A signi-
ficant association was observed in the replication
analysis for the two genome-wide significant hits;
rs2470893 (P-value= 7.2 1005) and rs2472297
(P-value = 1.91005) in the CYP1A1/CYP1A2 region
(Table 2, Figure 2). The meta-analysis of the discovery
and replication cohorts showed a strongly significant
association of rs2470893 (P-value = 1.61011) and
rs2472297 (P-value = 2.71011). Among marginally
significant SNPs in the genome-wide analysis, the
SNP rs382140 near the NRCAM gene also showed
significant association in the replication analysis
(P-value = 1.31003). The meta-analysis of the
discovery and replication cohorts yielded a genome-
wide significant association of rs382140 with coffee
drinking (P-value = 3.91009) (Table 2, Figure 2).
rs6495122 also showed nominal significance in the
replication analysis (P-value = 0.02). Although this
P-value did not pass the Bonferroni threshold, the
meta-analysis of discovery and replication cohorts
showed genome-wide significant association of
Figure 1 Regional association plot for 15q24. The vertical axis shows the negative logarithm of the association P-values, and
the horizontal axis shows the position in mega bases. Each dot represents an SNP and the colors of the dots represent the
extent of linkage disequilibrium with the top SNP, which is colored in purple. Genes in the region are shown below the
horizontal axis.
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rs6495122 with coffee drinking (P-value = 7.11009)
(Table 2, Figure 2).
Additional evidence of association was sought from
independent GWAS performed by the deCODE,
including samples from Iceland (n=3027) and The
Netherlands (Nijmegen) (n=2812). These studies
performed GWAS on coffee consumption in cups
per day only among coffee drinkers. Among the
marginally significant findings in the GWAS, only
the SNP rs9526558 in the CAB39L gene showed
consistent direction and size of the effect estimate
but an insignificant association in the deCODE
samples (Supplementary Table 4). In contrast, the
CYP1A1/CYP1A2 region is significantly associated
with coffee consumption in this data set (rs2472297,
P-value= 5.4 1014),75 underscoring a robust associa-
tion at the CYP1A1/CYP1A2 loci.
Expression analyses
First, we evaluated to what extent the SNPs above are
associated with a differential expression in public
expression databases. For none of the SNPs discussed
above, there was evidence for altered expression in
the brain.71 Supplementary Table 5 shows that
rs2470893 is involved in the expression of the COX5A
gene (P-value = 1.21004). Moreover, the second
locus in the region tagged by rs2470893 is associated
with COX5A expression. Of the four regions that did
not reach genome-wide significance, only the chro-
mosome 7 region shows evidence of differential
expression in lymphocytes. rs382140 is associated
with the expression of the SEMA3D gene
(P-value = 2.01004), a gene most likely involved in
axonal guidance. However, this SNP is also associated
with the expression of several other genes in trans
including SUCLG2, TOLLIP, NRG2 and HFE. Of these
genes, HFE is most well known in coffee research,
being one of the major genes involved in iron
metabolism. The protective effect of coffee for risk
of type II diabetes mellitus is suggested to be at least
partially explained by the iron absorption inhibitory
effect of coffee.76,77
Figure 2 Forest plot for the top hits from the GWAS. Vertically left, the populations included in the GWAS and the
replication phase. The boxes represent precision and horizontal lines represent the confidence intervals. The diamond
represents the pooled effect estimate from the meta-analysis of all cohorts. The horizontal axis shows the scale of the effects.
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Next, we examined to what extent caffeine alters
expression of the genes, which are tagged by the
associated SNPs reported above. A total of 647
autosomal genes were found to be differentially
expressed in all three types of cell lines (data not
shown). CYP1A1 encoding the protein that meta-
bolizes polycyclic aromatic hydrocarbons was
found to be downregulated by caffeine in LCLs
(fold-change =1.29, P-valueadj = 5.381008, b=9.54),
but no evidence of differential expression after
caffeine treatment was observed for CYP1A2 or the
NRCAM genes in any of the three cell types. However,
the enzyme encoded by the CYP1A2 gene acts
primarily in the liver as part of the cytochrome P450
system, and we did not treat any liver-derived cell
lines. CAB39L was differentially expressed in all
three cell types. The change in expression after
caffeine treatment was most pronounced in LCLs
(fold-change =0.23, P-valueadj = 3.8 1027, b=55.03).
In combination with GWAS results, with finding,
this finding suggests that CAB39L is involved in
caffeine metabolism and intake. There are two probes
on the Illumina array that represent the NRCAM
gene. However, neither of these probes was in the
differentially expressed gene lists for all three cell
line types. That is, gene expression of NRCAM
was not found to be differentially expressed after
treatment with caffeine.
In the pathway analysis, we included 4886 genes
that were differentially expressed in at least 1 cell
type and in total 147 pathways were tested (Supple-
mentary Table 6). The pathway analysis suggests
significant overrepresentation of genes in the ubiqui-
tin proteasome pathway (P-value = 2.2 1005), p53
(P-value = 3.51005), Parkinson’s disease (P-value =
3.61005), purine biosynthesis (P-value= 9 1005)
and cell-cycle (P-value= 1.4 1004) pathways. Genes
involved in various metabolic processes were signi-
ficantly overrepresented (P-value= 5.61056).
Coffee-related phenotypes
We tested for the association of the top hits from the
GWAS with two established coffee-related pheno-
types: blood pressure and AD. For blood pressure and
hypertension, we used the data from CHARGE
(Cohorts for Heart and Aging Research in Genomic
Epidemiology). A significant association was found
for the top hit rs2470893 with systolic (P-value =
5 1003) and diastolic blood pressure (P-value =
1.61004), and a borderline association was
observed with hypertension (P-value = 0.02). The ‘T’
allele which was associated with increased coffee
drinking was also associated with increased blood
pressure. This association appears to be independent
of rs6495122 (Figure 1, r2 = 0.175), which was
found to be associated with blood pressure in a
previous study.78 For AD, we used the data from
RS and two previously published GWASs on AD.79,80
No association of any of the SNPs tested was detected
with AD.T
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Discussion
We conducted a meta-analysis of GWAS on coffee
consumption from 8 cohorts comprising > 18000
individuals of Northern European ancestry and
attempted replication of our top findings from the
GWAS in another B8000 individuals from an inde-
pendent cohort. Successful replication of the two
genome-wide significant hits rs2470893 and
rs2472297, which are also in strong LD and located
between the CYP1A1 and CYP1A2 genes, and
differential expression of the CYP1A1 gene after
caffeine treatment in LCLs strongly implicates the
CYP1A1/CYP1A2 locus in coffee drinking. Our study
also suggests significant association of an SNP
rs382140 in the promoter region of the NRCAM gene
with coffee drinking, and the combined results from
association (rs9526558) and expression analyses
implicate CAB39L in coffee drinking. Although
significant heterogeneity was detected at the
CYP1A1/CYP1A2 locus (PHET = 0.01) and the random
effects model did not show genome-wide signi-
ficance. Figure 2 highlights that the effect estimates
were largely consistent across all populations. The
CYP1A1/CYP1A2 locus is also significantly impli-
cated recently in a separate meta-analysis of GWAS of
coffee drinking conducted by deCODE in B6000
coffee drinkers75 and a GWAS on caffeine intake81
further strengthening our data.
Caffeine is known to be metabolized primarily by
CYP1A2 in the liver, and hence CYP1A2 has long been
a candidate gene for coffee consumption. A previous
study showed that C- >A polymorphism in the intron I
of CYP1A2 was associated with increased caffeine
metabolism.82 The CYP1A2 gene encodes a P450
enzyme involved in O-de-ethylation of phenacetin.83
The human hepatic microsomal caffeine 3-demethyla-
tion, which is the initial major step in caffeine
biotransformation in humans, is selectively catalyzed
by CYP1A2.83 CYP1A1 encodes the member P1-450 of
the cytochrome P450 superfamily of enzymes. P1-450
is most closely associated with polycyclic-hydro-
carbon-induced aryl hydrocarbon hydroxylase
(AHH) activity and is known to metabolize polycyclic
aromatic hydrocarbons such as benzo(a)pyrene, which
is a constituent of coffee known to be involved in
carcinogenesis.13 The CYP1A1 and CYP1A2 genes are
separated by a 23-kb segment that contains no other
open-reading frames. They are in opposite orienta-
tion, revealing that they share a common 50 flanking
region.84 Cytochrome P450 genes are a superfamily of
heme-containing mono-oxygenases that metabolize
many xenobiotics, including drugs, carcinogens and
toxicants, as well as endogenous compounds such as
fatty acids and neurotransmitters. CYP1A1 has been
identified in the human brain85 and localized to the
cortical regions, midbrain, basal ganglia and cerebel-
lum,86 whereas CYP1A2 has been found in most brain
regions examined.87,88
A third SNP—rs6495122—approached genome-
wide significance (P=8.22 1008). This SNP is also
located on chromosome 15, but is not in strong LD
with the genome-wide significant SNPs (r2 = 0.175
and r2 = 0.086, respectively). The secondary condi-
tional analysis in RS-II suggests that an association
signal at rs6495122 is partially independent of the top
hit in this region (rs2470893). A previous meta-
analysis found this SNP to be significantly associated
with diastolic blood pressure, and nominally asso-
ciated with systolic blood pressure and hyperten-
sion.78 There is evidence that suggest that caffeine
consumption is associated with an increase in blood
pressure. Consuming a dose of caffeine equivalent to
2–3 cups of coffee (200–250mg) has been found to
increase both systolic and diastolic blood pressure.10
Results from studies examining the long-term effects
of caffeine on blood pressure and risk to hypertension
have been mixed.21 Our studies underscore a joint
genetic background of coffee consumption and blood
pressure.
Of the non-15q24 loci, rs382140 near the NRCAM
is an interesting locus. This SNP showed a P-value
of 3.9 1009 in the association analysis. The SNP
rs382140 did not show evidence of association in
the deCODE sample. The reason may be the exclusion
of non-drinkers in the deCODE sample as deCODE
restricted the analysis to those who drink coffee.
NRCAM encodes neuronal cell adhesion molecule, is
expressed in the brain and is involved in several
aspects of nervous system development. Allelic
variants of this gene have been associated with
autism89 and addiction vulnerability.90,91 Genetic
variants that increase the risk to addiction may also
influence coffee consumption, as twin studies have
shown that there is some overlap in the heritability of
coffee consumption and use of nicotine and alco-
hol.92,93 Caffeine has been described as ‘a model drug
of abuse’26,94,95 and the finding of the NRCAM gene is
in line with this hypothesis, although we did find
NRCAM to be differentially expressed after caffeine
treatment. The expression of NRCAM was found to be
upregulated in papillary thyroid carcinomas.96
CAB39L was found to be upregulated in all three
cell types used in the expression analysis in this
study in addition to strong association signals in
the meta-analysis (rs9526558, P-value =6.8 1007).
The SNP rs9526558 was not available for replica-
tion because of bad imputation quality in the
replication cohort; however, in deCODE, it showed
consistency of the effect size and direction, although
significance was not achieved. This may be attributed
to the different study design and lower power of
the deCODE sample. CAB39L encodes calcium-bind-
ing protein 39-like, a gene that is expressed in the
brain. The function of this gene is not well character-
ized, but the encoded protein interacts with the
serine/threonine kinase 11 (STK11) gene. This gene,
which encodes a member of the serine/threonine
kinase family, regulates cell polarity and functions as
a tumor suppressor.
An intronic SNP in the gene NCALD also showed
suggestive evidence of association with coffee
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consumption (rs16868941 P=1.5 1007). Like
CAB39L, NCALD is involved in calcium metabolism.
NCALD encodes a member of the neuronal calcium
sensor family of calcium-binding proteins. The
protein is cytosolic at resting calcium levels but
elevated intracellular calcium levels induce a con-
formational change that exposes the myristoyl group,
resulting in protein association with membranes and
partial co-localization with the perinuclear trans-golgi
network. The protein is considered a regulator of G
protein-coupled receptor signal transduction. Several
alternatively spliced variants of this gene have
been determined, all of which encode the same
protein. The gene has shown to be associated with
diabetic nephropathy.97 Earlier we found evidence
for association of the NCALD gene with sleep latency
(rs17498920, P-value = 21005) (NA, unpublished
data). Coffee intake is known to interfere with
melatonin secretion,98 thereby delaying the onset of
sleep.
It is interesting to note that the pathway analysis
implicates both ubiquitin proteasome and Parkinson’s
disease pathways as being significantly enriched with
genes differentially expressed after caffeine treatment,
given that coffee/caffeine is known to protect against
Parkinson’s disease.99 Mutations in the PARKIN gene
are the most common cause of hereditary Parkinson-
ism, and Parkin is an enzyme that ubiquinates several
candidate substrate proteins, thereby targeting them
for proteasomal degradation.100
In this study, we have combined gene expression
data from three cell types treated with caffeine with
GWAS data to study genes implicated in coffee-
drinking habits in more detail. Studies that contrib-
uted to our GWAS came from different countries.
Differences across studies and within a study, for
instance cup size and caffeine content could have led
to a loss of power in gene discovery. Significant
heterogeneity between studies was observed at the
CYP1A1/CYP1A2 locus, although the effect estimates
were consistent. To overcome the problem of hetero-
geneity, we also performed a random effects meta-
analysis.
Our gene expression studies in lymphocytes
strengthen the evidence of association for CYP1A1
and CAB39L. Although in analyzing the effects of
caffeine, it would be most pertinent to study changes
in other cells and tissues including the liver and
brain tissues, there is some evidence to suggest
that gene expression in blood can be a good marker
of gene expression in the central nervous system,
and so LCLs may provide a good alternative.101 It
should be noted that the concentration of caffeine
we used is in the lower limit of that found in
the bloodstream after drinking a cup of coffee. A
recent study suggests that there are different patterns
of gene expression at various concentrations
of caffeine,25 and further studies of gene expres-
sion should use different concentrations of caffeine
within the normal range found after caffeine consum-
ption in humans.
The fact that an individual would choose to abstain
from coffee or drink only very small quantities may
relate to insomnia, anxiety, trembling or other side
effects of caffeine. It will likely be informative to
test whether carriers of coffee consumption alleles
experience the same or different side effects from
caffeine. Analysis of individuals according to caffeine
symptoms and compared with controls may provide
more power for detecting caffeine-sensitive alleles.
Our study is an important step in understanding the
genetics of coffee/caffeine consumption. Caffeine is
the most used psychoactive drug in the world,
and coffee is the most common form of caffeine
consumption among adults. Therefore, our results
have implications not only for understanding indivi-
dual differences in caffeine consumption but also
for many other human traits and diseases such
as blood pressure. Previous overlap in SNPs identi-
fied for caffeine-induced anxiety and panic
disorder indicate that an understanding of how
caffeine mediates its effects will help decipher the
genetics of anxiety and anxiety disorders. Similarly,
other studies have identified interactions between
long-term caffeine use, common variants and risk of
disease and our results can inform future studies in
these areas.
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